Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
04
2021
accepted:
20
07
2021
pubmed:
9
8
2021
medline:
8
9
2021
entrez:
8
8
2021
Statut:
ppublish
Résumé
Breast cancer-related lymphedema (BCRL) is a source of postoperative morbidity for breast cancer survivors. Lymphatic microsurgical preventive healing approach (LYMPHA) is a technique used to prevent BCRL at the time of axillary lymph node dissection (ALND). We report the 5-year experience of a breast surgeon trained in LYMPHA and investigate the outcomes of patients who underwent LYMPHA following ALND for treatment of cT1-4N1-3M0 breast cancer. A retrospective review of patients with cT1-4N1-3M0 breast cancer was performed in patients who underwent ALND with and without LYMPHA. Diagnosis of BCRL was made by certified lymphedema therapists. Descriptive statistics and lymphedema surveillance data were analyzed using results of Fisher's exact or Wilcoxon rank-sum tests. Logistic regression and propensity matching were performed to assess the reduction of BCRL occurrence following LYMPHA. In a 5-year period, 132 patients met inclusion criteria with 76 patients undergoing LYMPHA at the time of ALND and 56 patients undergoing ALND alone. Patients who underwent LYMPHA at the time of ALND were significantly less likely to develop BCRL than those who underwent ALND alone (p = 0.045). Risk factors associated with BCRL development were increased patient age (p = 0.007), body mass index (BMI) (p = 0.003), and, in patients undergoing LYMPHA, number of positive nodes (p = 0.026). LYMPHA may be successfully employed by breast surgeons trained in lymphatic-venous anastomosis at the time of ALND. While research efforts should continue to focus on prevention and surveillance of BCRL, LYMPHA remains an option to reduce BCRL and improve patient quality of life.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer-related lymphedema (BCRL) is a source of postoperative morbidity for breast cancer survivors. Lymphatic microsurgical preventive healing approach (LYMPHA) is a technique used to prevent BCRL at the time of axillary lymph node dissection (ALND). We report the 5-year experience of a breast surgeon trained in LYMPHA and investigate the outcomes of patients who underwent LYMPHA following ALND for treatment of cT1-4N1-3M0 breast cancer.
METHODS
METHODS
A retrospective review of patients with cT1-4N1-3M0 breast cancer was performed in patients who underwent ALND with and without LYMPHA. Diagnosis of BCRL was made by certified lymphedema therapists. Descriptive statistics and lymphedema surveillance data were analyzed using results of Fisher's exact or Wilcoxon rank-sum tests. Logistic regression and propensity matching were performed to assess the reduction of BCRL occurrence following LYMPHA.
RESULTS
RESULTS
In a 5-year period, 132 patients met inclusion criteria with 76 patients undergoing LYMPHA at the time of ALND and 56 patients undergoing ALND alone. Patients who underwent LYMPHA at the time of ALND were significantly less likely to develop BCRL than those who underwent ALND alone (p = 0.045). Risk factors associated with BCRL development were increased patient age (p = 0.007), body mass index (BMI) (p = 0.003), and, in patients undergoing LYMPHA, number of positive nodes (p = 0.026).
CONCLUSIONS
CONCLUSIONS
LYMPHA may be successfully employed by breast surgeons trained in lymphatic-venous anastomosis at the time of ALND. While research efforts should continue to focus on prevention and surveillance of BCRL, LYMPHA remains an option to reduce BCRL and improve patient quality of life.
Identifiants
pubmed: 34365563
doi: 10.1245/s10434-021-10551-8
pii: 10.1245/s10434-021-10551-8
pmc: PMC8840814
mid: NIHMS1750472
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5775-5787Subventions
Organisme : NHGRI NIH HHS
ID : T32 HG008958
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 HG000089
Pays : United States
Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Ann Surg Oncol. 2017 Oct;24(10):2818-2826
pubmed: 28766232
J Clin Oncol. 2015 Jan 20;33(3):258-64
pubmed: 25452445
Ann Surg Oncol. 2009 Mar;16(3):703-8
pubmed: 19139964
Eur J Surg Oncol. 2017 Apr;43(4):672-679
pubmed: 28139362
Ann Plast Surg. 2019 Apr;82(4S Suppl 3):S234-S241
pubmed: 30855393
N Engl J Med. 2002 Aug 22;347(8):567-75
pubmed: 12192016
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Semin Plast Surg. 2018 Feb;32(1):5-11
pubmed: 29636647
Ann Plast Surg. 2017 Jun;78(6S Suppl 5):S296-S298
pubmed: 28328630
Crit Rev Oncol Hematol. 2014 Dec;92(3):227-34
pubmed: 25085806
Lancet Oncol. 2013 Apr;14(4):297-305
pubmed: 23491275
World J Clin Oncol. 2014 Aug 10;5(3):241-7
pubmed: 25114841
PLoS One. 2016 Feb 26;11(2):e0150285
pubmed: 26919589
Curr Oncol. 2020 Dec;27(6):336-340
pubmed: 33380866
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Ann Surg Oncol. 2018 Dec;25(Suppl 3):685-686
pubmed: 30411271
Lymphat Res Biol. 2020 Aug;18(4):357-364
pubmed: 31944882
Breast Cancer Res Treat. 2017 Apr;162(2):201-215
pubmed: 28012086
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
Ann Surg Oncol. 2011 Sep;18(9):2500-5
pubmed: 21369739
N Engl J Med. 2019 Feb 14;380(7):694
pubmed: 30763181
Ann Surg Oncol. 2013 Jan;20(1):120-7
pubmed: 22956062
J Med Liban. 2009 Apr-Jun;57(2):65-71
pubmed: 19623880
Int Wound J. 2005 Mar;2(1):47-62
pubmed: 16722853
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
J Clin Oncol. 2008 Nov 10;26(32):5213-9
pubmed: 18838709
Lancet Oncol. 2016 Oct;17(10):e430-e441
pubmed: 27733269
J Surg Oncol. 2019 Aug;120(2):160-167
pubmed: 31144329
Surgery. 2014 Nov;156(5):1261-8
pubmed: 25444319
Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401
pubmed: 8092905
Ann Surg Oncol. 2007 Jun;14(6):1890-5
pubmed: 17479341
J Reconstr Microsurg. 2013 Feb;29(2):99-106
pubmed: 23254539
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):62-70
pubmed: 30165125
Psychooncology. 2017 Jun;26(6):849-855
pubmed: 27479170
Ann Surg Oncol. 2015 Oct;22(10):3296-301
pubmed: 26202566
Ann Surg. 1894 Nov;20(5):497-555
pubmed: 17860107
Ann Surg. 2010 Apr;251(4):595-600
pubmed: 20195151
Breast Cancer Res Treat. 2013 Nov;142(1):59-67
pubmed: 24122390
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
J Surg Res. 2019 Dec;244:604-611
pubmed: 29397949
J Am Acad Dermatol. 2012 Dec;67(6):1342-8
pubmed: 22682884
Cancer. 2019 Mar 15;125(6):854-862
pubmed: 30521080
Phys Ther. 2020 Jul 19;100(7):1163-1179
pubmed: 32589208
Plast Reconstr Surg. 2014 Jul;134(1):154e-160e
pubmed: 25028830
Phys Ther. 2012 Jan;92(1):152-63
pubmed: 21921254
Microsurgery. 2014 Sep;34(6):421-4
pubmed: 24677148